With a $25 million commitment, Elanco Animal Health is entering the corporate venture capital space to capture emerging breakthroughs in animal therapeutics and supportive technology. The new platform, Elanco Ventures, aims to secure a stronger foothold in the startup ecosystem when it officially begins operations in late 2026.
The initiative marks a strategic pivot for the Indianapolis-based company, which plans to target early-stage businesses in the Pre-Seed, Seed, and Series A phases. By investing directly into these ventures, Elanco seeks to expand its reach beyond internal research and development, tapping into external innovation to meet rising global demand for livestock protein and advanced veterinary pet care.
Eric Steager, a veteran in corporate venture capital, will lead the fund. His team will prioritize investments that align with the "One Health" concept, which views the health of animals, humans, and plants as interconnected. The fund will work in tandem with the One Health Innovation District in Indianapolis, a collaborative hub anchored by Elanco and Purdue University designed to compress the timeline between laboratory discovery and commercial delivery.
CEO Jeff Simmons noted that the landscape of animal health is evolving too rapidly for any single firm to capture every advancement alone. By positioning itself at the center of this innovation district, Elanco hopes to identify and scale technologies that redefine standard care practices. Tim Bettington, Executive Vice President for Strategic Growth, added that this collaborative model is intended to break down traditional industry barriers, ensuring the company remains at the forefront of the sector as it navigates a shifting global market.
Comments (0)
No comments yet. Be the first!